

Quarterly DRUG REPORT

First Quarter 2024

As a valued partner of Companion Life Insurance Company, **CompanionCARE** strives to keep you up to date on the latest advances in pharmacotherapy.

Stay up to date on industry news:

Because we

Cost-effective alternatives

Analysis of claims and clinical referrals

Resource for health care trends and benchmarks

Education and training opportunities



Specialty Drugs Approved in the First Quarter 2024

Drug name	Condition Treated	Cost
Winrevair	Pulmonary artery hypertension	275K annually
Amtagvi	Melanoma	575K annually
Lenmeldy gene therapy	Metachromatic leukodystrophy	4.25M one-time dose + admin \$
Carvykti	Multiple myeloma	Moved from 5 th to 2 nd line therapy
Abecma	Multiple myeloma	Moved from 5 th to 3 rd line therapy
Hyrimoz (Humira biosimilar)	Psoriatic and rheumatoid arthritis	97K annually
Fasenra	Asthma	45K annually
Duvyzat	Duchenne muscle dystrophy	465K annually
Ultomiris	Neuromyelitis optica spectrum	480K annually
Iclusig	Acute lymphocytic leukemia	190K annually



CAR-T for Lupus

About a dozen companies have launched trials testing cell therapies for lupus, according to a federal database. Two cell therapy leaders, Novartis and Bristol Myers Squibb, started Phase 1 trials last year. They're each testing newer versions of the products they brought to market for cancer, tweaking them to cut manufacturing times, boost safety and raise potency. Lupus has several types, the most common of which is known as systemic lupus erythematosus, or SLE. It affects multiple organs and can have multiple symptoms—there is no cure. Available treatments can help manage symptoms and counteract the immune response associated with the disease, but the condition can still result in kidney failure or death from heart-related complications. More recently, three medicines specifically developed for lupus — GSK's Benlysta, Aurinia Pharmaceuticals' Lupkynis and AstraZeneca's Saphnelo — have reached the market. All have limitations and not everyone responds to treatment. Researchers are not using the same approach to cell therapy. The targets vary and studies are in early stages.

[LEARN MORE](#)

Questions, concerns, feedback?

Please contact Debbie Hoffer, Assistant Vice President of CompanionCARE at Debbie.Hoffer@CompanionLife.com or 260-609-7906.

™ All rights reserved. This message is intended only for the use of the individual or entity to which it is addressed, and may contain information that is privileged, confidential, and exempt from disclosure under applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution, or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to its sender.